Under the partnership, Providence’s 52 hospitals will use Grail’s Galleri test, a test that can detect more than 50 types of cancers using a single drop of blood, according to an April 4 press release from Grail.
“As a complement to current cancer screening programs, we believe the novel Galleri test offers an innovative way to assist with early cancer detection, especially with patients at high risk for difficult to detect cancers,” said Ora Karp Gordon, MD, regional medical director of Providence’s clinical genetics and genomics program.
St. Louis-based Mercy is also using these tests in 11 of its hospital’s labs.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.